Objectives: To evaluate the efficacy of stapes surgery in patients presenting with a preoperative mixed hearing loss (bone conduction thresholds ≥40 dB; 40 < air conduction thresholds (AC) < 85 dB). Patients and Methods: A total of 30 patients (32 ears) with mixed hearing loss who underwent primary stapedotomy were evaluated. Audiometric parameters were assessed before and after surgery. Contralateral thresholds were also reported. The need for a hearing aid (HA) after surgery and its impact on quality of life were also measured. Results: AC and word recognition at 40, 55 and 70 dB were significantly improved after stapes surgery. Only 16.6% of the patients needed an HA after surgery and reported being satisfied with the aid. Conclusion: Stapes surgery improved auditory function in patients with mixed hearing loss, allowing most patients to delay the need for an HA without worsening their quality of life.

1.
Cox RM, Alexander GC: The International Outcome Inventory for Hearing Aids (IOI-HA): psychometric properties of the English version. Int J Audiol 2002; 41: 30–35.
2.
Cox RM, Stephens D, Kramer SE: Translations of the International Outcome Inventory for Hearing Aids (IOI-HA). Int J Audiol 2002; 41: 3–26.
3.
Garcia-Iza L, Navarro JJ, Goiburu M, Perez N, Altuna X: Study of the improvement in bone conduction threshold after stapedectomy. Acta Otorrinolaringol Esp 2016; 67: 268–274
4.
Gurgel RK, Jackler RK, Dobie RA, Popelka GR: A new standardized format for reporting hearing outcome in clinical trials. Otolaryngol Head Neck Surg 2012; 147: 803–807.
5.
House HP, Sheehy JL: Stapes surgery: selection of the patient. Ann Otol Rhinol Laryngol 1962; 70: 1062–1068.
6.
Ishai R, Halpin CF, Shin JJ, McKenna MJ, Quesnel AM: Long-term incidence and degree of sensorineural hearing loss in otosclerosis. Otol Neurotol 2016; 37: 1489–1496.
7.
Han JJ, Park SY, Park SN, Na MS, Lee P, Han JS: Cochlear function tests in estimation of speech dynamic range. Acta Otolaryngol 2016; 136: 1041–1045.
8.
Kabbara B, Gauche C, Calmels MN, Lepage B, Escude B, Deguine O, Fraysse B, Marx M: Decisive criteria between stapedotomy and cochlear implantation in patients with far advanced otosclerosis. Otol Neurotol 2015; 36:e73–e78.
9.
Lachance S, Bussières R, Côté M: Stapes surgery in profound hearing loss due to otosclerosis. Otol Neurotol 2012; 33: 721–723.
10.
Redfors YD, Hellgren J, Möller C: Hearing-aid use and benefit: a long-term follow-up in patients undergoing surgery for otosclerosis. Int J Audiol 2013; 52: 194–199.
11.
Redfors YD, Möller C: Otosclerosis: thirty-year follow-up after surgery. Ann Otol Rhinol Laryngol 2011; 120: 608–614.
12.
Salmon C, Barriat S, Demanez L, Magis D, Lefebvre PP: Audiometric results after stapedotomy operations in patients with otosclerosis and preoperative small air-bone gaps. Audiol Neurotol 2015; 20: 330–336.
13.
Shiao AS, Kuo CL, Cheng HL, Wang MC, Chu CH: Controversial issues of optimal surgical timing and patient selection in the treatment planning of otosclerosis. Eur Arch Otorhinolaryngol 2014; 271: 1007–1014.
14.
Van Loon MC, Merkus P, Smit CF, Smits C, Witte BI, Hensen EF: Stapedotomy in cochlear implant candidates with far advanced otosclerosis: a systematic review of the literature and meta-analysis. Otol Neurotol 2014; 35: 1707–1714.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.